Quantcast

Latest Atypical antipsychotics Stories

2014-09-11 23:01:41

The Firm is representing numerous Risperdal lawsuit plaintiffs who allegedly developed gynecomastia, or male breast growth, due to their use of the antipsychotic drug. New York, New York (PRWEB) September 11, 2014 A Canadian project investigating the use of Risperdal (http://www.lawreward.com/risperdal/) and other antipsychotic medications in elderly dementia patients has reported positive outcomes when the drugs are reduced in this patient population, Bernstein Liebhard LLP reports....

2014-08-25 23:00:16

New Study Finding Supports Allegations in over 700 Risperdal Lawsuits of the Development of Male Breast Enlargement after Taking Risperdal, Reports Wright & Schulte LLC Columbus, OH (PRWEB) August 26, 2014 A recently released study supports claims in Risperdal lawsuits that the antipsychotic drug Risperdal can cause the develop gynecomastia, or abnormal breast growth. In the study published on August 6, 2014, in the Journal of Clinical Psychopharmacology, researchers from the...

2014-08-19 23:02:22

The Firm is representing men and boys in Risperdal lawsuits who allegedly developed gynecomastia (male breast growth) due to their use of the atypical antipsychotic medication. New York, New York (PRWEB) August 19, 2014 As Risperdal lawsuits (http://www.risperdallawsuitcenter.com) mount in U.S. courts, Bernstein Liebhard LLP notes the publication of a new study that suggests the use of atypical antipsychotic medications may increase the risk of acute kidney injury in elderly patients....

2014-08-09 23:03:20

Risperdal Lawsuit Claims Continue to Be Filed Against Johnson & Johnson Contending Male Breast Growth Due to the Manufacturer’s Antipsychotic Drug Risperdal Reports Wright & Schulte LLC Columbus, OH (PRWEB) August 09, 2014 Risperdal lawsuits currently pending litigation in the Philadelphia Court of Common Pleas in Pennsylvania have grown to 662 Risperdal lawsuit claims filed against the makers of the antipsychotic drug, notes Wright & Schulte LLC. According to the court...

2014-07-14 08:26:29

Submission based on first head-to-head study vs. oral treatments in real world context TITUSVILLE, N.J., July 14, 2014 /PRNewswire/ -- Janssen Pharmaceuticals, Inc. today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking a label change that, if approved, would include new data showing significantly delayed time to relapse in patients prescribed once-monthly atypical long-acting antipsychotic INVEGA(®)...

2014-05-14 08:30:09

PITTSBURGH, May 14, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that it has launched Olanzapine Orally Disintegrating Tablets (ODT), 5 mg, 10 mg, 15 mg and 20 mg, the generic version of Eli Lilly and Company's Zyprexa Zydis(®) Tablets. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the treatment of schizophrenia or the acute treatment of manic or...

2014-05-13 08:33:18

New submission based on positive data from a 15-month schizoaffective relapse prevention study TITUSVILLE, N.J., May 13, 2014 /PRNewswire/ -- Janssen Pharmaceuticals, Inc., today announced the submission of supplemental New Drug Applications (sNDAs) for once-monthly atypical long-acting antipsychotic INVEGA(®) SUSTENNA(®) (paliperidone palmitate) to the U.S. Food and Drug Administration (FDA) for approval to treat schizoaffective disorder as either monotherapy or adjunctive...

2014-05-06 16:32:22

Demonstrated significant efficacy in manic and depressive mood symptoms and psychosis, and improved patient functioning TITUSVILLE, N.J., May 6, 2014 /PRNewswire/ -- Janssen Pharmaceuticals, Inc., today announced the results of the company's schizoaffective relapse prevention study of once-monthly atypical long-acting antipsychotic INVEGA(®) SUSTENNA(® )(paliperidone palmitate). The trial found INVEGA(®) SUSTENNA(®) met its primary endpoint of delayed time to and reduced risk of...

2014-05-05 08:29:33

First prospective, randomized clinical trial to reflect context of "real world" issues in treating schizophrenia, including recent incarceration and substance abuse TITUSVILLE, N.J., May 5, 2014 /PRNewswire/ -- Janssen Pharmaceuticals, Inc., today announced the results of its landmark PRIDE (Paliperidone Palmitate Research In Demonstrating Effectiveness) trial. PRIDE is the first prospective, randomized clinical trial to compare schizophrenia medications within the context of many...

2014-04-22 08:34:04

TITUSVILLE, N.J., April 22, 2014 /PRNewswire/ -- Janssen Pharmaceuticals, Inc., and Janssen Research and Development, LLC, both members of the Johnson & Johnson Family of Companies, announced that several posters related to the company's work in mental health will be featured at the 167(th) Annual Meeting of the American Psychiatric Association (APA) in New York City May 3 to 7. The posters are: -- Paliperidone Palmitate Research in Demonstrating Effectiveness (PRIDE):...


Word of the Day
caparison
  • A cloth or covering, more or less ornamented, laid over the saddle or furniture of a horse, especially of a sumpter-horse or horse of state.
  • Clothing, especially sumptuous clothing; equipment; outfit.
  • To cover with a caparison, as a horse.
  • To dress sumptuously; adorn with rich dress.
This word ultimately comes from the Medieval Latin 'cappa,' cloak.
Related